Investment
Features
FeesSafety
Academy
More
Pluang+

Ørsted remains a Buy with strong H1 2026 growth and UK tax win despite recent share drop.

Analyst Insights
15 Sep 2026
Seeking Alpha
View Source
Bullish
Ørsted remains a Buy with strong H1 2026 growth and UK tax win despite recent share drop.

Ørsted continues to be rated a Buy due to strong revenue growth in the first half of 2026 and a favorable UK tax ruling that could reduce future tax expenses and boost net profits. The company trades at a lower valuation compared to its historical average, suggesting potential upside as earnings grow. Short-term challenges include US policy uncertainty and impairments from higher interest rates, but Ørsted's leading position in offshore wind energy supports cautious long-term optimism for investors.

Ørsted's cautious optimism is presented here alongside Pluang's snapshot of the Energy sector as of Sep 16, 2026 04:52 WIB. Among 30 priced US energy stocks on Pluang, 20 advanced while 10 declined. Devon Energy Corp (DVN) rose 3.87% to USD 51.32, Valero Energy Corporation (VLO) increased 3.78% to USD 397.42, and ConocoPhillips (COP) gained 3.37% to USD 141.28, showing notable strength compared to their 52-week ranges.

More News

New crypto Pepeto raises $11.23M amid Ethereum's bullish $10,000 price forecast for 2026.

New crypto Pepeto raises $11.23M amid Ethereum's bullish $10,000 price forecast for 2026.

Pepeto, a new cryptocurrency on the Ethereum network, has quickly raised over $11.23 million in its presale, with each funding stage closing faster than the last. This momentum comes as Ethereum is predicted to reach $10,000 by the end of 2026, drive...

Market News
Bullish
39 minutes ago
BlackRock's stake in Fagron drops below 3% after share transfers, holding 2.96% voting rights as of October 2026.

BlackRock's stake in Fagron drops below 3% after share transfers, holding 2.96% voting rights as of October 2026.

BlackRock, Inc. disclosed that its voting rights in pharmaceutical company Fagron NV fell below the 3% reporting threshold due to the transfer of voting securities, despite acquiring financial instruments equivalent to voting rights. As of October 12...

Market News
Neutral
1 hour ago
FDA approves phentolamine eye drops for presbyopia, offering a new treatment for age-related near vision loss.

FDA approves phentolamine eye drops for presbyopia, offering a new treatment for age-related near vision loss.

Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% for treating presbyopia, an age-related condition affecting near vision in adults. This approval, based on successful Phase 3 trials, provides a non-invasive option that i...

Market News
Bullish
1 hour ago
K2 Vision performs 5,000 Light Adjustable Lens procedures, leading globally in this advanced vision tech.

K2 Vision performs 5,000 Light Adjustable Lens procedures, leading globally in this advanced vision tech.

K2 Vision has completed over 5,000 procedures using the Light Adjustable Lens (LAL), making it the highest-volume practice worldwide for this technology. The LAL is unique because it can be adjusted after implantation to fine-tune vision based on the...

Market News
Bullish
1 hour ago
BlackRock's stake in Fagron falls below 3% after share disposals, now holding 2.96% voting rights.

BlackRock's stake in Fagron falls below 3% after share disposals, now holding 2.96% voting rights.

BlackRock, Inc. disclosed that its shareholding in Fagron NV dropped below the 3% threshold to 2.96% after selling some voting securities, despite acquiring equivalent financial instruments. As of October 12, 2026, BlackRock holds 2,015,779 voting ri...

Market News
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App